LBRX
NASDAQLB Pharmaceuticals Inc
News25/Ratings8
News · 26 weeks55-50%
2026-03-012026-08-23
Mix2990d
- SEC Filings12(41%)
- Insider8(28%)
- Other5(17%)
- Leadership2(7%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 10-Q filed by LB Pharmaceuticals Inc10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAnnounced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company")
- INSIDERSEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Announces $150 Million Private PlacementNEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that it has entered into a securities purchase agreement to sell 3,577,560 shares of its common stock and pre-funded warrants to purchase up to 715,513 shares of its common stock to a limited group of institutional investors in a private placement. The purchase price of each share of common stock is $34.94. The purchase price of each pre-funded warrant is $34.9399, which represents the per share pu
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 8-K filed by LB Pharmaceuticals Inc8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in SchizophreniaNEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and s
- ANALYSTBMO Capital Markets initiated coverage on LB Pharmaceuticals with a new price targetBMO Capital Markets initiated coverage of LB Pharmaceuticals with a rating of Outperform and set a new price target of $46.00
- SECSEC Form SCHEDULE 13G filed by LB Pharmaceuticals IncSCHEDULE 13G - LB PHARMACEUTICALS INC (0001691082) (Subject)
- PRLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals. Mr. Zergebel received an option to purchase 75,000 shares of LB Pharmaceuticals’ co
- ANALYSTWolfe Research initiated coverage on LB Pharmaceuticals with a new price targetWolfe Research initiated coverage of LB Pharmaceuticals with a rating of Outperform and set a new price target of $45.00
- PRLB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical OperationsNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management. "We ar
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 8-K filed by LB Pharmaceuticals Inc8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 144 filed by LB Pharmaceuticals Inc144 - LB PHARMACEUTICALS INC (0001691082) (Subject)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 8-K filed by LB Pharmaceuticals Inc8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- INSIDERSEC Form 4 filed by Director Ruffolo Robert R4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Nussbaum Ran4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Luse Rebecca4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by Director Lenz Robert A.4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
LBRX FAQ
6 questionsWhere does LBRX stock trade?
LB Pharmaceuticals Inc (LBRX) is listed on NASDAQ.What sector and industry is LBRX in?
LB Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LB Pharmaceuticals Inc go public?
LB Pharmaceuticals Inc (LBRX) completed its IPO in 2025.What are analysts saying about LBRX?
LB Pharmaceuticals Inc has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform with a $4600.00 price target on 2026-07-21. Recent price targets range from $2700.00 to $4600.00.What companies are similar to LBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LBRX side-by-side with any of them on Quantisnow.How can I track LBRX on Quantisnow?
Quantisnow aggregates LB Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LBRX to receive live email and push alerts on every new disclosure.